Form 4: Unicycive Director Converts Preferred Stock to Common

Unicycive Therapeutics Director Gaurav Aggarwal converted 3,199.21 shares of Series A-2 Prime Preferred Stock into 652,900 shares of common stock.

Summary

• Gaurav Aggarwal, a Director of Unicycive Therapeutics, Inc. (UNCY), converted Series A-2 Prime Preferred Stock into common stock.
• The transaction occurred on August 25, 2025.
• A total of 3,199.21 shares of Series A-2 Prime Preferred Stock were converted.
• This resulted in the acquisition of 652,900 shares of common stock.
• Following the transaction, 1,789,915 shares of common stock are beneficially owned indirectly by Vivo Opportunity Fund Holdings L.P.
• Each share of Series A-2 Prime Preferred Stock is convertible into common stock by dividing the original per share price of $1,000 by $4.90.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned conversion of preferred stock to common stock by a director. This is a neutral event, reflecting a standard capital structure adjustment rather than a significant positive or negative operational development. The Rule 10b5-1(c) plan indicates a lack of discretionary timing.

Positives

• Conversion of preferred stock to common stock can simplify the capital structure and increase the float of common shares.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary transaction.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing, common in the biotechnology and pharmaceutical sectors where early investors or directors often hold convertible preferred stock that converts to common stock as the company matures or meets certain milestones. It does not directly reflect broader industry trends but is a standard capital structure event.

Related Party Transactions

• The transaction involves Gaurav Aggarwal, a Director of Unicycive Therapeutics, Inc., converting preferred stock held indirectly through Vivo Opportunity Fund Holdings L.P. into common stock. This is a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The conversion increases the number of common shares outstanding, potentially diluting existing common shareholders. However, it also simplifies the capital structure by reducing preferred stock.
• Investors: Provides transparency regarding insider holdings and capital structure changes.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned conversion of preferred stock to common stock by a director. Such a transaction, especially under a Rule 10b5-1(c) plan, is a standard capital structure event and does not typically provide new information that would warrant a change in investment recommendation. It reflects a pre-existing agreement rather than a new discretionary decision by the insider based on recent company performance or outlook. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Unicycive Therapeutics, UNCY, Gaurav Aggarwal, Form 4, Insider Transaction, Stock Conversion, Preferred Stock, Common Stock, Beneficial Ownership, Vivo Opportunity Fund